Chronic Rhinosinusitis Trial, Recruiting NCT06776042 Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Chronic Rhinosinusitis Trial, Recruiting

NCT06776042
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have had at least two of these symptoms for 12 weeks or more: blocked nose, runny nose, loss of smell, or pain/pressure in the face
  • A camera examination of your nose has shown polyps (small growths) on both sides of your nasal passages
  • A smell test shows your sense of smell is below a certain level, and you also feel your smell has reduced
  • A blood test shows you have a higher than normal level of a type of white blood cell called eosinophils (a sign of certain types of inflammation)
  • You have been using a nasal steroid spray consistently for at least 4 weeks

Who may not be able to join:

  • You are currently a smoker
  • You have a condition that affects your immune system, either from birth or developed later in life
  • You have a condition affecting the tiny hairs in your airways, such as cystic fibrosis or primary ciliary dyskinesia (confirm with trial site)
  • You have had, or currently have, a cancerous growth in your nose or sinuses
  • You are younger than 18 or older than 70 years of age
  • You are unable to give your own consent to take part in the trial
  • You have used steroid tablets, injections, or other systemic steroids within the 4 weeks before your first visit
  • You have used antibiotic tablets, injections, or antibiotic nasal treatments within the 4 weeks before your first visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Valérie Hox, MD, PhD, Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phone: +3227648675

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Registry
ClinicalTrials.gov
Start date
22 May 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Genetic profile comparison after single-cell RNA sequencing

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov